Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Trastuzumab Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0166

    Trastuzumab Agents

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0166 alerts

    Get alerted when Policy CC-0166 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-benefit coverage and clinical review, including prior authorization and step therapy, for Herceptin, Herceptin Hylecta, and specified trastuzumab biosimilars used for HER2-overexpressing breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma.

    Policy Summary
    PayerEmpire Bluecross
    PolicyTrastuzumab Agents
    Policy CodePolicy CC-0166
    Change TypeModified
    Effective DateSep 1, 2026
    Last ReviewMay 15, 2026
    Next Review DateNot specified
    Key ActionFor a non-preferred trastuzumab agent, document either a trial and intolerance to one preferred trastuzumab agent or that the individual is currently stabilized on the requested non-preferred agent.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was revised on 09/01/2026 with updates to the trastuzumab step therapy table.

    The 09/01/2026 policy update revised the step therapy table.

    Hercessi was added to prior authorization and step therapy criteria in the 06/10/2024 select review.

    Step therapy for the Medicaid line of business was added on 12/21/2020.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    8Trastuzumab products identified
    7Agents subject to primary approval criteria
    2Exceptions supporting a non-preferred agent
    8HCPCS codes for covered products
    2Commercial preferred agents
    4Boxed-warning risks identified

    Coverage Criteria

    Herceptin and Trastuzumab Biosimilars

    Requests may be approved when the requested product is one of the following trastuzumab agents:

    Covered trastuzumab reference or biosimilar agent: The request is for Herceptin (trastuzumab), Ogivri (trastuzumab-dkst), Herzuma (trastuzumab-pkrb), Ontruzant (trastuzumab-dttb), Trazimera (trastuzumab-qyyp), Hercessi (trastuzumab-strf), or Kanjinti (trastuzumab-anns).

    Herceptin Hylecta

    Requests may be approved when:

    The request is for Herceptin Hylecta (trastuzumab; hyaluronidase-oysk).

    Coding Information

    HCPCSHCPCS
    J9355Injection, trastuzumab, excludes biosimilar, 10 mg [Herceptin]
    J9356Injection, trastuzumab, 10 mg and hyaluronidase-oysk (Herceptin Hylecta)
    Q5112Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg
    Q5113Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg
    Q5114Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg
    Q5116Injection, trastuzumab-qyyp, biosimilar, (Trazimera), 10 mg
    Q5117Injection, trastuzumab-anns, biosimilar, (Kanjinti), 10 mg
    Q5146Injection, trastuzumab-strf (Hercessi), biosimilar, 10 mg
    All DiagnosesICD-10
    No codes listed
    HCPCS codes referenced in policy historyHCPCS
    J9355HCPCS code; description updated in the 05/16/2025 policy history
    J3590HCPCS code added in the 06/10/2024 review and later deleted
    Q5146HCPCS code for Hercessi, added effective 01/01/2025
    HCPCS codes referenced in policy historyHCPCS
    J9356HCPCS code listed in the 05/15/2020 coding update
    J9355HCPCS code listed in the 05/15/2020 coding update
    Q5113HCPCS code listed in the 05/15/2020 coding update
    Q5117HCPCS code listed in the 05/15/2020 coding update
    Q5114HCPCS code listed in the 05/15/2020 coding update
    Q5112HCPCS code listed in the 05/15/2020 coding update
    Q5116HCPCS code listed in the 05/15/2020 coding update

    Provider Actions and Utilization Management

    Documentation Required

    Preferred-Agent Exception Criteria

    A request for a non-preferred trastuzumab agent may be approved when the individual has tried and experienced intolerance to one preferred trastuzumab agent, or when the individual is currently stabilized on the requested non-preferred agent.

    • Document the preferred-agent trial and intolerance, or document current stabilization on the requested agent.
    Note

    Commercial Medical Benefit

    For the commercial medical benefit, use the preferred trastuzumab agents when clinically appropriate. Herceptin and Kanjinti are preferred effective 01/01/2025; the remaining listed agents are non-preferred.

    • Preferred: Herceptin, Kanjinti
    • Non-preferred: Herzuma, Hercessi, Ogivri, Ontruzant, Trazimera

    Background

    Trastuzumab is a monoclonal antibody that targets HER2/neu receptors. This policy addresses trastuzumab products—including Herceptin, Herceptin Hylecta, and specified biosimilars—for HER2-overexpressing adjuvant and metastatic breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. The products carry boxed warnings for cardiomyopathy, infusion reactions, pulmonary toxicity, and embryo-fetal toxicity; the risk of cardiac failure is greatest when trastuzumab is administered concurrently with anthracyclines.

    Definitions

    Adjuvant or adjunctive treatment
    DefinitionTreatment given after the primary treatment to increase the chances of a cure and may include chemotherapy, radiation, hormone or biological therapy.
    Metastasis
    DefinitionThe spread of cancer from one part of the body to another; a metastatic tumor contains cells that are like those in the original (primary) tumor and have spread.
    Monoclonal antibody
    DefinitionA protein developed in the laboratory that can locate and bind to specific substances in the body and on the surface of cancer cells.
    Targeted biologic agent

    Initial Therapy Criteria

    Herceptin and Trastuzumab Biosimilars

    Requests may be approved when the requested product is one of the following trastuzumab agents:

    Covered trastuzumab reference or biosimilar agent: The request is for Herceptin (trastuzumab), Ogivri (trastuzumab-dkst), Herzuma (trastuzumab-pkrb), Ontruzant (trastuzumab-dttb), Trazimera (trastuzumab-qyyp), Hercessi (trastuzumab-strf), or Kanjinti (trastuzumab-anns).

    Herceptin Hylecta

    Requests may be approved when:

    The request is for Herceptin Hylecta (trastuzumab; hyaluronidase-oysk).

    Continuation Therapy Criteria

    Continuation of Current Non-Preferred Therapy

    A non-preferred trastuzumab agent may be approved when either of the following criteria is met:

    ONE of

    • The individual has had a trial and intolerance to one preferred trastuzumab agent.
    • The individual is currently stabilized on the requested non-preferred trastuzumab agent.

    Step Therapy Requirements

    StepRequirementException
    1Use a preferred trastuzumab agent before approval of a non-preferred trastuzumab agent.A non-preferred agent may be approved if the individual has had a trial and intolerance to one preferred trastuzumab agent or is currently stabilized on the requested non-preferred agent.
    Effective datePreferred agentsNon-preferred agents
    01/01/2025Herceptin; KanjintiHerzuma; Hercessi; Ogivri; Ontruzant; Trazimera
    Applicable cohort and effective datePreferred agentsNon-preferred agents
    NV — 10/01/2022, through 01/01/2026; LA — 11/01/2022KanjintiHerceptin; Herzuma; Ogivri; Ontruzant; Trazimera
    IA — 10/01/2025; NJ, NY, VA — 11/01/2025; DC (through 08/01/2026), GA, MD, WNY, SC, TN — 12/01/2025; OH — 01/01/2026; AR, IN — 02/01/2026; WI — 03/01/2026KanjintiHerceptin; Hercessi; Herzuma; Ogivri; Ontruzant; Trazimera
    WA — 10/01/2026KanjintiHerceptin; Herzuma; Ogivri; Ontruzant; Trazimera
    Effective datePreferred agentsNon-preferred agents
    09/01/2025Herceptin; KanjintiHercessi; Herzuma; Ogivri; Ontruzant; Trazimera

    Biosimilar and Reference-Agent Information

    Billing Rule

    Use the preferred trastuzumab list

    The policy provides a linked list of preferred trastuzumab agents. Preferred agents are considered clinically comparable to other agents in the same class or disease category and are selected based on clinical evidence and cost effectiveness.

    • Review the linked step therapy table for the applicable line of business.
    • Preferred status does not eliminate the policy’s step therapy requirements for non-preferred agents.
    Billing Rule

    Commercial preference: Kanjinti and Herceptin

    For the commercial medical benefit effective 01/01/2025, Kanjinti is identified in the preferred-agent relationship with Herceptin: both Herceptin and Kanjinti are preferred, while Herzuma, Hercessi, Ogivri, Ontruzant, and Trazimera are non-preferred.

    • Preferred: Herceptin, Kanjinti
    Policy Summary
    PayerEmpire Bluecross
    PolicyTrastuzumab Agents
    Policy CodePolicy CC-0166
    Change TypeModified
    Effective DateSep 1, 2026
    Last ReviewMay 15, 2026
    Next Review DateNot specified
    Key ActionFor a non-preferred trastuzumab agent, document either a trial and intolerance to one preferred trastuzumab agent or that the individual is currently stabilized on the requested non-preferred agent.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider Actions and Utilization ManagementBackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy RequirementsBiosimilar and Reference-Agent Information
    Note

    Medicaid Medical Benefit

    For Medicaid cohorts with the listed effective dates, Kanjinti is preferred. Cohort coverage includes NV and LA beginning 10/01/2022 and 11/01/2022, respectively; IA, NJ, NY, VA, DC, GA, MD, WNY, SC, TN, OH, AR, IN, WI, and WA become applicable on the dates specified below.

    • Preferred: Kanjinti
    • Non-preferred for NV/LA cohorts: Herceptin, Herzuma, Ogivri, Ontruzant, Trazimera
    • Non-preferred for IA, NJ, NY, VA, DC, GA, MD, WNY, SC, TN, OH, AR, IN, WI, and WA cohorts: Herceptin, Hercessi, Herzuma, Ogivri, Ontruzant, Trazimera
    • Effective dates: 10/01/2022 NV (until 01/01/2026); 11/01/2022 LA; 10/01/2025 IA; 11/01/2025 NJ, NY, VA; 12/01/2025 DC (until 08/01/2026), GA, MD, WNY, SC, TN; 01/01/2026 OH; 02/01/2026 AR, IN; 03/01/2026 WI; 10/01/2026 WA.
    Note

    Medicare Medical Benefit

    For the Medicare medical benefit effective 09/01/2025, use Herceptin or Kanjinti as preferred agents. Hercessi, Herzuma, Ogivri, Ontruzant, and Trazimera are non-preferred.

    • Preferred: Herceptin, Kanjinti
    • Non-preferred: Hercessi, Herzuma, Ogivri, Ontruzant, Trazimera
    Denial Risk

    Denial Risk Without an Exception

    A request for a non-preferred trastuzumab agent is at risk for denial when neither exception pathway is met: there is no documented intolerance after a trial of a preferred agent and the individual is not currently stabilized on the requested agent.

    • Do not rely on non-preferred selection alone; submit documentation supporting intolerance or stabilization.
    Step Therapy

    Non-Preferred Agent Selection

    Select a preferred trastuzumab agent first when initiating therapy. A non-preferred agent requires utilization-management review under step therapy and should be supported by documentation of intolerance to a preferred agent or current stabilization on the requested agent.

    • Apply the applicable benefit-specific preferred-agent list and effective date.
    • For a non-preferred request, document the step-therapy exception before submission.
    DefinitionA newer type of drug developed specifically to target genetic changes in cells that cause cancer. It works differently than standard chemotherapy drugs, often with different side effects.
  1. Non-preferred: Herzuma, Hercessi, Ogivri, Ontruzant, Trazimera
  2. Billing Rule

    Medicaid preference: Kanjinti over Herceptin

    For the Medicaid medical benefit, Kanjinti is the preferred agent in the applicable state and effective-date cohorts. Herceptin is non-preferred in those cohorts, along with Hercessi, Herzuma, Ogivri, Ontruzant, and Trazimera where listed.

    • Preferred: Kanjinti
    • Non-preferred: Herceptin, Hercessi, Herzuma, Ogivri, Ontruzant, Trazimera
    Billing Rule

    Medicare preference: Kanjinti and Herceptin

    For the Medicare medical benefit effective 09/01/2025, Kanjinti is a preferred agent alongside Herceptin. Hercessi, Herzuma, Ogivri, Ontruzant, and Trazimera are non-preferred.

    • Preferred: Herceptin, Kanjinti
    • Non-preferred: Hercessi, Herzuma, Ogivri, Ontruzant, Trazimera